NASDAQ
MYOK

MyoKardia, Inc

Prices are adjusted according to historical splits.

MyoKardia, Inc Stock Price

Vitals

Today's Low:
$224.9100
Today's High:
$224.9100
Open Price:
$224.9100
52W Low:
$42.65
52W High:
$140.9277
Prev. Close:
$224.9100
Volume:
0

Company Statistics

Market Cap.:
$7.399 billion
Book Value:
17.155
Revenue TTM:
$0.012 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-26.54%
Return on Equity TTM:
-44.75%

Company Profile

MyoKardia, Inc had its IPO on 2015-10-29 under the ticker symbol MYOK.

The company operates in the sector and industry. MyoKardia, Inc has a staff strength of 275 employees.

Stock update

Shares of MyoKardia, Inc opened at $224.91 at the start of the last trading session i.e. 2020-11-17.

The stocks traded within a range of $224.91 - $224.91, and closed at $224.91.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of MyoKardia, Inc have increased by +0.41%.

MyoKardia, Inc's Key Ratios

MyoKardia, Inc has a market cap of $7.399 billion, indicating a price to book ratio of 7.9525 and a price to sales ratio of 0.

In the last 12-months MyoKardia, Inc’s revenue was $0.012 billion with a gross profit of $0.000 billion and an EBITDA of $-0.115 billion. The EBITDA ratio measures MyoKardia, Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, MyoKardia, Inc’s operating margin was 0% while its return on assets stood at -26.54% with a return of equity of -44.75%.

In Q2, MyoKardia, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

MyoKardia, Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-7.073 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MyoKardia, Inc’s profitability.

MyoKardia, Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

MyoKardia, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

MyoKardia, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

MyoKardia, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

MyoKardia, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, MyoKardia, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, MyoKardia, Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$224.91
52-Week High
$140.9277
52-Week Low
$42.65
Analyst Target Price
$137.45

MyoKardia, Inc stock is currently trading at $224.91 per share. It touched a 52-week high of $140.9277 and a 52-week low of $140.9277. Analysts tracking the stock have a 12-month average target price of $137.45.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 14.67 indicating a short percent outstanding of 10%.

Around 378.7% of the company’s stock are held by insiders while 10799.5% are held by institutions.

Frequently Asked Questions About MyoKardia, Inc

The stock symbol (also called stock or share ticker) of MyoKardia, Inc is MYOK

The IPO of MyoKardia, Inc took place on 2015-10-29

Similar Industry Stocks ()

Last Price
Chg
Chg%
$10.75
-0.25
-2.27%
$35.81
-0.45
-1.24%
$22.01
0.06
+0.27%
$2
-0.13
-6.1%
$2.76
-0.06
-2.13%
Vectrus, Inc (VEC)
$0
0
0%
$0.28
-0.02
-5.67%
$1.9
0
0%
$11.4
-0.23
-1.98%
$43.85
-0.89
-1.99%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company; and a strategic collaboration and license agreement with Fulcrum Therapeutics, Inc. to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Address

333 Allerton Avenue, South San Francisco, CA, United States, 94080